Alzheimer’s disease is the most common cause of dementia, affecting an estimated 55 million people worldwide — a number projected to nearly triple by 2050 as populations age. Characterised by progressive memory loss, cognitive decline, and behavioural changes, Alzheimer’s gradually destroys the brain’s ability to function, ultimately proving fatal. Despite decades of research and billions of dollars invested, effective treatments remain elusive, though recent breakthroughs in understanding the disease’s biology and promising new drug approaches are generating cautious optimism.
What Happens in the Alzheimer’s Brain
The Alzheimer’s brain is marked by two pathological hallmarks. Amyloid plaques — clumps of misfolded amyloid-beta protein — accumulate between neurons, disrupting cell-to-cell communication. Neurofibrillary tangles — twisted fibres of hyperphosphorylated tau protein — form inside neurons, blocking the transport of nutrients and other essential molecules. Together, these pathologies trigger widespread neuroinflammation, synaptic loss, and neuronal death, particularly in the hippocampus (the brain’s memory centre) and cerebral cortex.
The disease process begins decades before symptoms appear. Amyloid plaques may start forming 15 to 20 years before a patient notices memory problems, followed by tau tangles, neuroinflammation, and finally clinical symptoms. This long preclinical phase has reshaped research strategy — many scientists now believe that intervention must begin early, before extensive neuronal damage has occurred.
The Amyloid Hypothesis and Beyond
For three decades, the amyloid hypothesis — the idea that amyloid-beta accumulation is the primary driver of Alzheimer’s — dominated research and drug development. However, numerous clinical trials of anti-amyloid drugs failed to slow cognitive decline, leading many researchers to question whether amyloid is a cause, a consequence, or merely a correlate of the disease.
The approval of lecanemab (Leqembi) in 2023 and donanemab in 2024 — antibody therapies that clear amyloid plaques from the brain — provided the first evidence that removing amyloid can modestly slow cognitive decline in early-stage patients. While the clinical benefits were statistically significant, they were modest (roughly 25-35 percent slowing of decline), and the drugs carry risks including brain swelling and microbleeds.
These results suggest that amyloid does play a role in the disease but is not the whole story. Research increasingly focuses on other mechanisms: tau propagation, neuroinflammation driven by microglial cells, metabolic dysfunction, vascular contributions, and the role of the immune system in brain health.
Risk Factors and Prevention
While age and genetics (particularly the APOE4 gene variant) are the strongest risk factors for Alzheimer’s, research has identified modifiable lifestyle factors that significantly influence risk. The Lancet Commission on dementia prevention identified 14 modifiable risk factors that together account for roughly 45 percent of dementia cases worldwide, including limited education, hearing loss, hypertension, obesity, smoking, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, and social isolation.
Regular physical exercise, cognitive engagement, social interaction, cardiovascular health management, adequate sleep, and a Mediterranean-style diet have all been associated with reduced Alzheimer’s risk in large epidemiological studies. Clinical trials of multidomain lifestyle interventions (such as the FINGER study) have shown measurable cognitive benefits in at-risk populations.
Future Directions
The next wave of Alzheimer’s research is pursuing multiple fronts simultaneously. Blood-based biomarkers that can detect Alzheimer’s pathology through a simple blood test are approaching clinical deployment, enabling earlier diagnosis and screening for prevention trials. Gene therapy approaches aim to modify Alzheimer’s risk genes. Anti-tau therapies target the other hallmark pathology. And combination approaches — treating amyloid, tau, and inflammation simultaneously — may prove more effective than targeting any single mechanism.
The field is also increasingly recognising that Alzheimer’s is not a single disease but a syndrome with multiple biological subtypes, each potentially requiring different treatment strategies. Personalised medicine approaches that match patients to treatments based on their specific biological profile represent the long-term vision for Alzheimer’s therapeutics.
